Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4091627
Max Phase: Preclinical
Molecular Formula: C17H22N4O4
Molecular Weight: 346.39
Molecule Type: Small molecule
Associated Items:
ID: ALA4091627
Max Phase: Preclinical
Molecular Formula: C17H22N4O4
Molecular Weight: 346.39
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccc2cccc(NC(=O)NOCCCCCC(=O)NO)c2n1
Standard InChI: InChI=1S/C17H22N4O4/c1-12-9-10-13-6-5-7-14(16(13)18-12)19-17(23)21-25-11-4-2-3-8-15(22)20-24/h5-7,9-10,24H,2-4,8,11H2,1H3,(H,20,22)(H2,19,21,23)
Standard InChI Key: JOPWBNICMMDOAU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 346.39 | Molecular Weight (Monoisotopic): 346.1641 | AlogP: 2.66 | #Rotatable Bonds: 8 |
Polar Surface Area: 112.58 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.61 | CX Basic pKa: 4.01 | CX LogP: 1.62 | CX LogD: 1.60 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.33 | Np Likeness Score: -1.14 |
1. Stenzel K, Hamacher A, Hansen FK, Gertzen CGW, Senger J, Marquardt V, Marek L, Marek M, Romier C, Remke M, Jung M, Gohlke H, Kassack MU, Kurz T.. (2017) Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines., 60 (13): [PMID:28581289] [10.1021/acs.jmedchem.6b01538] |
Source(1):